[ad_1]
John Ryan is just one of the miracles to emerge from the Johns Hopkins Cancer Unit in Baltimore. An immunotherapy treatment – very effective in a minority of patients – saved her life after a diagnosis of lung cancer.
Retired Nuclear Reactor Specialist Celebrates 74th Anniversary in July, Fighting Cancer Illustrates Promises and Failures of Immunotherapy, a Growing Field in Which the Pharmaceutical Industry Invests massively.
Ryan was able to witness the graduations of three of his children, and will be attending the wedding of one of his daughters this summer – even though doctors are waiting for it to happen. was only 18 months to live in June 2013.
"It's exciting," he said.
But he knows a lot of people who have not been so fortunate.
five years old, I lost a lot of friends.
Immunotherapy is one of two major categories of cancer drugs. The best known is chemotherapy, used for decades and aimed at killing tumors, but which is so toxic that it also attacks healthy cells, causing major side effects such as weakness, pain, diarrhea, nausea and hair. [19659008Ryanatraversetoutcain2013etsatumeursoristed
Exhausted by chemo and ravaged by pain, Ryan was accepted into a final clinical trial using nivolumab (brand name Opdivo) at the end of 2013.
the drug was administered intravenously to the patient. hospital, first every two weeks, then once a month.
Her tumor disappeared quickly, and 104 injections later, the main side effect was an itch
. his right lung.
"They shot me with chemo, it almost killed me, and now I've started taking immunotherapy, and it's been good, my quality of life was excellent, "said Ryan
. – Relatively Few Patients –
Immunotherapy forms the body's natural defenses – immune cells, also called T cells – to detect and kill cancer cells, which otherwise may adapt and hide.
Some experts are cautious, been repeatedly disappointed by other innovative approaches to the fight against cancer.
But many consider immunotherapy as a turning point. According to Otis Brawley, medical director of the American Cancer Society, more than 30 immunotherapy drugs are under development and 800 clinical trials are underway.
Julie Brahmer, Ryan's oncologist, said that she was now starting about one-third of her lung cancer patients. on immunotherapy first, not on chemotherapy
It is helpful that many clinical trials are underway at the Baltimore facility, far more than the average US hospitals.
Exceptionally long remissions observed in a small number of Ryan patients. These success stories account for approximately 10 to 15 percent of patients, said William Nelson, director of Johns Hopkins' Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Normal remissions usually last between one and a half years and two years
. radiation is still the most dominant tool.
But in recent years, a series of clinical trials have shaken the world of cancer, showing that it was possible to better treat and even cure some of the most difficult forms of cancer without resorting to
] – Personalized Treatments –
A Spectacular Example Regarding Prostate Cancer
Researchers found that recommendations for regular screening had the opposite effect of what was expected: too many tumors which would never have spread.
Regarding breast cancer, a major study published early June at the American Society of Clinical Oncology conference showed that women, surgery, and hormone therapy were enough to ward off the Cancer. They discovered that chemotherapy was unnecessarily used, which surprised the cancer community.
Meanwhile, genetic testing is becoming more common for tumors, allowing more accurate and faster treatments for patients.
Laboratory specifically designed to help physicians customize patients' treatments, rather than basing treatment simply on the location of the tumor.
"At this point, we have better tools to say," Yes, it needs to be cured. "Some cancers, including brain cancer, remain on the sidelines of these new treatments
but for leukemia, breast cancer, lung cancer, cervix, colon and rectum, as well as serious skin cancer known as melanoma, immunotherapy and other personalized treatments progresses slowly but surely, says Nelson.
For the role of oncologist Julie Brahmer, she hopes that someday, metastatic cancers – those that can spread to distant points of the locus of Origin – will be treated as a "chronic disease" rather than a death sentence.
John Ryan has a simpler goal in mind
"My goal is to die of something else. A laboratory scientist is manipulating a culture of Hodgkin's lymphoma cells from within. a refrigerator at the Ludwig Center for Cancer Genetics and Therapeutics, at Johns Hopkins Hospital, June 21, 2018 in Baltimore, Maryland
Doctors were waiting for John Ryan to be 18 months in live in June 2013 while he had been diagnosed with lung cancer but that immunotherapy had gotten rid of his tumor
William Nelson runs the Sidney Kimmel Comprehensive Cancer Center at 39 Johns Hopkins Hospital Tumors at the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins Hospital
A Gene Sequencer is Visualized at the Ludwig Center for Cancer Genetics and Therapeutics
Source link
